VijayPD Ceutical
- Market cap
- ₹ 161 Cr.
- P/E
- 29.6x
- P/B
- 2.99x
- 52-week range
- 37.5 – 114.5
- ROE
- 12%
- ROCE
- 11.6%
- Dividend yield
- 0%
- Debt / equity
- 0.7
- Sector
- Electrical Equipment
- Industry
- Heavy Electrical Equipment
- Listed on
- NSE SME
About
VijayPD Ceutical Ltd is engaged in the business of distributing and supplying the pharmaceutical and consumer goods sectors. The Company provides a range of products, serving both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market, including pharmaceutical and wellness products such as medicines, including injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. It also supplies vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. The Company also provides personal care and toiletry products, including soaps, sanitizers, and baby care items. It also deals in ayurvedic products, cosmetics, food products, dental products, and crude drugs. The Company operates three distribution warehouses located in Mumbai. It delivers healthcare solutions to pharmacies, nursing homes, and clinics across Western Suburban Mumbai, South Mumbai, Ratnagiri, Aurangabad and Akola.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Heavy Electrical Equipment: 51 companies →VijayPD Ceutical against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)29.6 against a typical 30.6: cheaper than most peers (1st = cheapest).22nd of 50
- Share price, 3 months+19.2% against a typical −7.8%.5th of 45
- Size₹ 161 Cr. market value against a typical ₹ 5,357.9 Cr. (1st = largest).41st of 47
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 14 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 50 | 50 | 51 | 48 |
| Expenses | 45 | 47 | 47 | 47 |
| Operating Profit | 5 | 3 | 4 | 0 |
| OPM % | 10.9% | 5.9% | 8.5% | 0.7% |
| Other Income | 0 | 1 | 0 | 4 |
| Interest | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 4 | 2 | 3 | 3 |
| Tax % | 26.6% | 26.1% | 27.8% | 16.7% |
| Net Profit | 3 | 2 | 2 | 3 |
| EPS in Rs | 4.21 | 1.25 | 1.73 | 1.35 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 25%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 204%
- TTM
- 8%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| VijayPD Ceutical | ₹ 79.30 | ₹ 161 Cr. | 29.6x | 3x | 12% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 26.2x | 2.5x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 81.3x | 16x | — | 21% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 29.4x | 5.3x | — | 28.6% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 49.8x | 1.4x | — | 13.2% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.7x | 5.5x | — | 15.5% |
Management
- Samit Madhukar Shah
- Executive Chairman, Managing Director
- Chirag K. Thakkar
- Chief Financial Officer
- Madhuri Ganesh Batwal
- Company Secretary, Compliance Officer
- Bhavin Dhirendra Shah
- Whole Time Director
- Rahul Jitendra Shah
- Whole Time Director
- Narendra Nagindas Shah
- Non-Executive Non-Independent Director
Prices are delayed and for information only. Nothing on this page is investment advice.